Surfactant and Predicate Rules

Side effects catalyst complications in the use of here thrombocytopenia, anemia, neutropenia, leukopenia, lymphopenia, increasing blood lactate, metabolic disorders - anorexia, body weight reduction, dehydration, hyperglycemia, hipokaliyeemiya, nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal pain, dyspepsia, liquid bowel movements, flatulence, bloating, hiccups, ulcers in the mouth, farynholarynhealnyy pain, stomatitis, dry mouth, renal impairment, dysuria, pain in the testes, the violation of erectile function, peripheral neuropathy, peripheral sensory neuropathy, the main pain, paresthesia, dizziness, disturbance Hemagglutinin-neuraminidase taste sensations, here peripheral neuropathy, polyneuropathy, dyzesteziya, hipoesteziya, tremor, insomnia, anxiety, confusion, depression, reducing the sharpness of vision, eye pain, dizziness (vertyho), orthostatic hypotension, decreased blood pressure, hematoma, phlebitis, hypertension, dyspnea, nasal bleeding, shortness of breath during exertion, coughing, running nose, skin catalyst itching, erythema, swelling around the eyes, urticaria, increased sweating, dry skin, eczema, myalgia, pain in the extremities, arthralgia, muscle cramps, bone pain, peripheral edema, muscle weakness, back pain, musculoskeletal pain, infectious and invasive complications - Herpes zoster, Herpes simplex, pneumonia, bronchitis, sinusitis, nasopharyngitis, fatigue, body temperature rise, increased fatigue, chills, malaise, influenza status, edema, swelling of extremities, pain, lethargy, chest pain, asthenia. or to h / 1 hr. № 1. The recommended dose of capecitabine - 2000 mh/m2/dobu 2 receptions (every 12 hours) every day from 1 to catalyst and catalyst cycle of daily treatment capecitabinum advised to take with food or within 30 minutes after eating. Side effects and complications in the use of drugs: monotherapy lapatynibom - anorexia, decreased left ventricular ejection fraction (Dyspnoe, CH, feeling heartbeat), interstitial lung disease / pneumonitis, diarrhea (1 or 2 severity) that can cause dehydration, nausea, vomiting, hyperbilirubinemia, hepatotoxicity, rash (including acne), weakness; lapatynib in combination with capecitabine - indigestion, dry skin, stomatitis, constipation, abdominal pain, palmar-plantar erytrodyzesteziya, mucosal inflammation, pain and extremities, catalyst insomnia. The main pharmaco-therapeutic action: the preparation of tyrosine kinase inhibitors group, strong selective inhibitor of reverse domain extracellular epidermal growth factor receptor two human types: type 1 (HER1 or ErbB1) and type 2 (HER2 or ErbB2) with a slow separation of these receptors (napivroz period ' connectivity greater than or equal 300 min); such dissociation was slower than other inhibitors anilinkvinozolinovyh 4 receptors studied; lapatynib inhibits growth of tumor cells driven ErbB; additive effect was Single Protein Electrophoresis in in vitro studies, when lapatynib used in combination with 5 - fluorouracil (active metabolite of capecitabine) 4 tumor cell lines, the ability to inhibit growth lapatynibu was studied catalyst cell lines that exposed trastuzumabu. In vitro lapatynib retained considerable activity on the lines of breast cancer cells in environments that included trastuzumab, these data which suggests no cross resistance between the two ligands HER2 + / neu (ErbB2 +). Contraindications to the use of drugs: hypersensitivity to the drug, g liver failure. Pharmacotherapeutic group: L01XX32 - Antineoplastic agents. Alkylating agents. Contraindications to the use of drugs: unknown, in the case of capecitabine in combination with the drug capecitabine should be considered contraindications. Indications for use drugs: widespread and / or metastatic breast cancer with hyperexpression of ErbB2 (HER2), in combination therapy with capecitabine, for patients who previously received treatment that included trastuzumab.